Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib

Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed sim...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Medicina (Kaunas)
Main Authors: Brunetti, Oronzo, Gnoni, Antonio, Licchetta, Antonella, Longo, Vito, Calabrese, Angela, Argentiero, Antonella, Delcuratolo, Sabina, Solimando, Antonio Giovanni, Casadei-Gardini, Andrea, Silvestris, Nicola
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2019
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6843290/
https://ncbi.nlm.nih.gov/pubmed/31640191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/medicina55100707
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki